---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-21-311286"
form_type: "8-K"
ticker: "RMD"
cik: "0000943819"
company_name: "RESMED INC"
filed_at: "2021-10-28T23:59:59+00:00"
generated_at: "2026-06-28T17:12:03.609903+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# ResMed reports Q1 FY2022 revenue $904M (+20% YoY), diluted EPS $1.39, non-GAAP EPS $1.51

## Summary
- Revenue $904.0M, up 20% YoY (19% constant currency); all segments grew double-digits.
- Diluted EPS $1.39 (+14% YoY); non-GAAP diluted EPS $1.51 (+19% YoY).
- Income from operations $261.9M (+21%); non-GAAP operating profit $280.7M (+18%).
- Board declared quarterly cash dividend of $0.42/share, payable Dec 16, 2021, record Nov 11.
- CEO cited strong demand but ongoing supply chain constraints limiting electronic components.

## SEC filing metadata
- accession: 0001193125-21-311286
- form_type: 8-K
- ticker: RMD
- cik: 0000943819
- company_name: RESMED INC
- filed_at: 2021-10-28T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/943819/000119312521311286/0001193125-21-311286-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/943819/000119312521311286/d801447d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-21-311286
- JSON: https://secwatch.observer/filing/0001193125-21-311286.json
- Plain text: https://secwatch.observer/filing/0001193125-21-311286.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.